Developing Optimized Treatment Plans for Patients with Dyslipidemia in the Era of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapeutics.

James A Underberg,M. Blaha,Elizabeth J. Jackson,Peter H. Jones
DOI: https://doi.org/10.1016/j.amjmed.2017.07.004
2017-07-21
Abstract:
What problem does this paper attempt to address?